Operating
Increase (Decrease) in Accounts and Other Receivables
Edwards Lifesciences Increase (Decrease) in Accounts and Other Receivables increased by 373.5% to $117.9M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 169.8%, from $43.7M to $117.9M. Over 2 years (FY 2022 to FY 2024), Increase (Decrease) in Accounts and Other Receivables shows a downward trend with a 20.0% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryLiquidity
SignalLower is better
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026May 6, 2026
How to read this metric
An increase consumes cash, while a decrease releases cash from working capital.
Detailed definition
This metric represents the net change in amounts owed to the company by customers for goods or services delivered on cre...
Peer comparison
Standard across all industries; peers with high growth often see higher receivables growth.
Metric ID:
operating_increase_decrease_in_accounts_and_other_receivablesHistorical Data
16 periods
| Q2 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $46.4M | $57.8M | $19.9M | $5.3M | $1.1M | $77.5M | $46.8M | $0 | $18.2M | $55M | -$23M | -$47.3M | -$105.9M | $43.7M | $24.9M | $117.9M |
| QoQ Change | — | +24.6% | -65.6% | -73.4% | -79.2% | >999% | -39.6% | -100.0% | — | +202.2% | -141.8% | -105.7% | -123.9% | +141.3% | -43.0% | +373.5% |
| YoY Change | — | — | -57.1% | — | — | +34.1% | +135.2% | -100.0% | >999% | -29.0% | -149.1% | — | -681.9% | -20.5% | +208.3% | +169.8% |
Range-$105.9M – $117.9M
CAGR+28.2%
Avg YoY Growth+96.7%
Median YoY Growth-20.5%
Increase (Decrease) in Accounts and Other Receivables at Other Companies
Frequently Asked Questions
- What is Edwards Lifesciences's increase (decrease) in accounts and other receivables?
- Edwards Lifesciences (EW) reported increase (decrease) in accounts and other receivables of $117.9M in Q1 2026.
- How has Edwards Lifesciences's increase (decrease) in accounts and other receivables changed year-over-year?
- Edwards Lifesciences's increase (decrease) in accounts and other receivables increased by 169.8% year-over-year, from $43.7M to $117.9M.
- What is the long-term trend for Edwards Lifesciences's increase (decrease) in accounts and other receivables?
- Over 2 years (2022 to 2024), Edwards Lifesciences's increase (decrease) in accounts and other receivables has grown at a 20.0% compound annual growth rate (CAGR), from $84.1M to -$121.2M.
- What does increase (decrease) in accounts and other receivables mean?
- The net change in money owed to the company by its customers.